Don Soland

Don Soland

Nessuna posizione attualmente

Patrimonio netto: 953 928 $ in data 31/05/2026

67 anni
Health Technology
Consumer Services

Profilo

Daniel B. Soland was Director-Worldwide Marketing Operations & VP at Corixa Corp.
from 1993 to 2002.
Served as President & Chief Executive Officer at Epigenesis Pharmaceuticals LLC from 2002 to 2005.
Held the position of President at Seqirus Vaccines Ltd. from 2005 to 2006.
Was President-Chiron Vaccines at Chiron Corp.
from 2005 to 2006.
Chief Operating Officer & Senior Vice President at Viropharma, Inc. from 2008 to 2014.
Chief Operating Officer & Senior Vice President at Shire ViroPharma, Inc. from 2008 to 2014.
Chief Executive Officer & Executive Director at uniQure NV in 2016.
Independent Director at ACADIA Pharmaceuticals, Inc. from 2015 to 2025.
Independent Director at DBV Technologies SA from 2015 to 2025.
Non-Executive Director at Oxford Biomedica Plc from 2015 to 2016.
Independent Director at KalVista Pharmaceuticals, Inc. from 2019 to 2022.
Chief Operating Officer & Senior Vice President at Idera Pharmaceuticals, Inc. from 2020 to 2022.
Director at Tarsa Therapeutics, Inc. Education includes undergraduate studies at the University of Iowa.

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValutazioneData di valutazione
29/05/2025 44.041 ( 0,03% ) 953 928 $ 31/05/2026

Precedenti posizioni note di Don Soland

SocietàPosizioneFine
ACADIA PHARMACEUTICALS INC. Direttore/Membro del Consiglio 30/10/2025
DBV TECHNOLOGIES Direttore/Membro del Consiglio 18/09/2025
Direttore operativo 28/09/2022
KALVISTA PHARMACEUTICALS, INC. Direttore/Membro del Consiglio 26/05/2022
UNIQURE N.V. Amministratore Delegato 22/09/2016
Vedi nel dettaglio l'esperienza di Don Soland

Formazione di Don Soland

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Relazioni

59

Relazioni di 1° grado

14

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Società collegate

Aziende private14

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Viropharma, Inc.

  1. Mercati
  2. Insiders
  3. Don Soland
- 40%: I migliori strumenti riservati agli abbonati per individuare le opportunità di investimento di domani.
g
:
:
ENTRA ORA